低风险前列腺癌的转录组异质性：是时候从前列腺癌风险评估（CAPRA）转向临床基因组风险评估了。 - Suppr | 超能文献

Transcriptomic Heterogeneity of Favorable-risk Prostate Cancer: Time To Move Past Cancer of the Prostate Risk Assessment (CAPRA) to Clinical-genomic Risk.

作者信息

Spratt Daniel E, Schaeffer Edward M

机构信息

Department of Radiation Oncology, University of Michigan, Ann Arbor, MI, USA.

Department of Urology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.

出版信息

Eur Urol. 2018 Oct;74(4):453-454. doi: 10.1016/j.eururo.2018.06.001. Epub 2018 Jun 12.

DOI:10.1016/j.eururo.2018.06.001

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Transcriptomic Heterogeneity of Favorable-risk Prostate Cancer: Time To Move Past Cancer of the Prostate Risk Assessment (CAPRA) to Clinical-genomic Risk.低风险前列腺癌的转录组异质性：是时候从前列腺癌风险评估（CAPRA）转向临床基因组风险评估了。

Eur Urol. 2018 Oct;74(4):453-454. doi: 10.1016/j.eururo.2018.06.001. Epub 2018 Jun 12.

2

Genomic Scores are Independent of Disease Volume in Men with Favorable Risk Prostate Cancer: Implications for Choosing Men for Active Surveillance.基因组评分与低危前列腺癌患者的肿瘤负荷无关：对主动监测患者选择的影响。

J Urol. 2018 Feb;199(2):438-444. doi: 10.1016/j.juro.2017.09.077. Epub 2017 Sep 20.

3

Risk assessment of metastatic recurrence in patients with prostate cancer by using the Cancer of the Prostate Risk Assessment score: results from 2937 European patients.应用前列腺癌风险评估评分预测前列腺癌患者转移复发风险：来自 2937 例欧洲患者的研究结果。

BJU Int. 2012 Dec;110(11):1714-20. doi: 10.1111/j.1464-410X.2012.11147.x. Epub 2012 Apr 23.

4

Validation of GEMCaP as a DNA Based Biomarker to Predict Prostate Cancer Recurrence after Radical Prostatectomy.GEMCaP 作为一种基于 DNA 的生物标志物，用于预测前列腺癌根治术后的复发。

J Urol. 2018 Mar;199(3):719-725. doi: 10.1016/j.juro.2017.09.071. Epub 2017 Sep 20.

5

Tissue-based Genomics Augments Post-prostatectomy Risk Stratification in a Natural History Cohort of Intermediate- and High-Risk Men.基于组织的基因组学在中高危男性自然史队列中增强了前列腺切除术后风险分层。

Eur Urol. 2016 Jan;69(1):157-65. doi: 10.1016/j.eururo.2015.05.042. Epub 2015 Jun 6.

6

Limited improvement of incorporating primary circulating prostate cells with the CAPRA score to predict biochemical failure-free outcome of radical prostatectomy for prostate cancer.将原发性循环前列腺细胞与CAPRA评分相结合，用于预测前列腺癌根治性前列腺切除术后无生化复发结局时，改善效果有限。

Urol Oncol. 2016 Oct;34(10):430.e17-25. doi: 10.1016/j.urolonc.2016.05.020. Epub 2016 Jul 2.

7

Evaluation of biochemical recurrence-free survival after radical prostatectomy by cancer of the prostate risk assessment post-surgical (CAPRA-S) score.通过前列腺癌术后风险评估（CAPRA-S）评分评估根治性前列腺切除术后无生化复发生存率。

Asian Pac J Cancer Prev. 2015;16(6):2527-30. doi: 10.7314/apjcp.2015.16.6.2527.

8

The Within-Group Discrimination Ability of the Cancer of the Prostate Risk Assessment Score for Men with Intermediate-Risk Prostate Cancer.前列腺癌风险评估评分对中危前列腺癌男性的组内歧视能力。

J Korean Med Sci. 2018 Jan 29;33(5):e36. doi: 10.3346/jkms.2018.33.e36.

9

The Cancer of the Prostate Risk Assessment (CAPRA) score predicts biochemical recurrence in intermediate-risk prostate cancer treated with external beam radiotherapy (EBRT) dose escalation or low-dose rate (LDR) brachytherapy.前列腺癌风险评估 (CAPRA) 评分可预测接受外照射放疗 (EBRT) 剂量递增或低剂量率 (LDR) 近距离放疗的中危前列腺癌的生化复发。

BJU Int. 2014 Dec;114(6):865-71. doi: 10.1111/bju.12587. Epub 2014 Mar 14.

10

Patient-specific Meta-analysis of 2 Clinical Validation Studies to Predict Pathologic Outcomes in Prostate Cancer Using the 17-Gene Genomic Prostate Score.使用17基因基因组前列腺评分对两项临床验证研究进行患者特异性荟萃分析，以预测前列腺癌的病理结果。

Urology. 2016 Mar;89:69-75. doi: 10.1016/j.urology.2015.12.008. Epub 2015 Dec 23.

引用本文的文献

1

Prostate Cancer Tumor Volume and Genomic Risk.前列腺癌肿瘤体积与基因组风险

Eur Urol Open Sci. 2023 Jan 7;48:90-97. doi: 10.1016/j.euros.2022.12.002. eCollection 2023 Feb.